ACTRN12623000667617招募中2 期
Efficacy and safety of two versus three high dose psilocybin-assisted therapy sessions in comparison to a placebo for treatment resistant major depressive disorder (TR-MDD): A double blind, 3-arm Phase 2b randomised controlled trial
Swinburne University of Technology, Hawthorn0 个研究点目标入组 160 人开始时间: 2023年6月21日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 160
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 65 Years（—）
- 性别
- All
入选标准
- •Adults aged 18 to 65 years.
- •- Those currently experiencing major depressive disorder (DSM-5) as determined by the SCID-5.
- •- Those with current moderate to severe depression according to the MADRS.
- •- Treatment-resistance using criteria adapted from current literature of research in major depression.
- •- Under the care of a psychiatrist, psychologist, physician, or GP.
- •- Proficiency in English.
- •- Safe tapering and wash-out of current antidepressant pharmacotherapy prior to baseline assessment, as confirmed by treating GP, psychiatrist, or physician.
- •- Abstinence from illicit or extra-medical drug and alcohol use for at least 2 days prior to each dose session.
- •- Participants who agree to have their drug dosing sessions recorded to video for treatment fidelity and clinical supervision within the study team.
- •- Participants who are able to swallow tablets.
排除标准
- •Key General Medical Exclusion Criteria:
- •- Patients in treatment in another clinical trial involving an investigational product.
- •- Any disorder with known CNS involvement, or other major CNS disease.
- •- Hepatic dysfunction.
- •- Known conditions putting participant at risk for hypercalcaemia,
- •- Cardiovascular conditions: uncontrolled hypertension, angina, a clinically significant ECG abnormality (e.g., atrial fibrillation), TIA in the last 6 months, stroke, or cerebrovascular disease, peripheral or pulmonary vascular disease.
- •- A diagnosis of epilepsy or previous seizures.
- •- Renal insufficiency.
- •- Insulin-dependent diabetes.
- •- Females who are pregnant or nursing or are trying to get pregnant, or become pregnant during the study.
- •- Current hypothyroidism.
- •- Weight less than 40 kg.
- •- Contraindicated medication (SSRIs, SNRIs, MAOIs), and either 1) do not wish to be tapered off this medication, or 2) it is deemed by trial psychiatrists or the participant’s usual treatment team that tapering the participant off their current medication would be inappropriate.
- •- Use of any illicit or extra-medical drugs or alcohol within the 2 days prior to each psilocybin dosing.
- •- Current use of any potent metabolic inducers or inhibitors
- •- Significant, uncorrected visual impairments (to ensure that they can read all study material).
- •Key Psychiatric Exclusion Criteria:
- •- Current or past history of meeting DSM-5 criteria for Schizophrenia, Psychotic Disorder (unless substance-induced or due to a medical condition), Bipolar I or II Disorder, or Mania.
- •- First degree relative with diagnosed Schizophrenia, Psychotic Disorder (unless substance-induced or due to a medical condition), Bipolar I or II Disorder or Mania.
- •- Currently meets DSM-5 criteria for Dissociative Disorder, Anorexia Nervosa, Bulimia Nervosa, or any psychiatric conditions judged to be incompatible with establishment of rapport or safe exposure to psilocybin.
- •- Unable to give adequate informed consent.
研究者
相似试验
已完成
不适用
Safety and efficacy of single-dose and triple-dose albendazole and mebendazole against soil-transmitted helminth infections in humansISRCTN47375023Swiss Tropical Institute (STI) (Switzerland)370
进行中（未招募）
4 期
A clinical trial to generate scientific evidence on the efficacy of a two-dose HPV vaccination regimen as compared to the current standard three-dose regimeCTRI/2009/091/000137WHO20,000
进行中（未招募）
1 期
Investigation of efficacy and safety of three dose levels of subcutaneous semaglutide once daily versus placebo in subjects with non-alcoholic steatohepatitis.on-alcoholic steatohepatitisMedDRA version: 19.0Level: PTClassification code 10053219Term: Non-alcoholic steatohepatitisSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2016-000685-39-FRovo Nordisk A/S372
进行中（未招募）
1 期
Investigation of efficacy and safety of three dose levels of subcutaneous semaglutide once daily versus placebo in subjects with non-alcoholic steatohepatitis.on-alcoholic steatohepatitisMedDRA version: 19.0Level: PTClassification code 10053219Term: Non-alcoholic steatohepatitisSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2016-000685-39-FIovo Nordisk A/S372
进行中（未招募）
1 期
Investigation of efficacy and safety of three dose levels of subcutaneous semaglutide once daily versus placebo in subjects with non-alcoholic steatohepatitis.on-alcoholic steatohepatitisMedDRA version: 20.1Level: PTClassification code 10053219Term: Non-alcoholic steatohepatitisSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2016-000685-39-DKovo Nordisk A/S288